6 citations
,
April 2013 in “Current Dermatology Reports” Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.
June 2025 in “Indus journal of bioscience research.” Oral tofacitinib is more effective than oral minoxidil for treating alopecia areata.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
February 2026 in “Molecules” BBR-SA nanomedicine is a safe and effective treatment for breast cancer.
December 2024 in “PubMed” Cyclosporine effectively treated a woman's stubborn skin condition.
September 2023 in “Acta dermato-venereologica” Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.
7 citations
,
January 2022 in “SAGE open medical case reports” Upadacitinib successfully treated a child's severe skin and hair loss issues.
19 citations
,
September 2006 in “Journal of Pediatric Gastroenterology and Nutrition” Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
April 2025 in “The Journal of Dermatology” Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.
2 citations
,
February 2022 in “Frontiers in Endocrinology” Antiandrogenic pretreatment for women with PCOS does not improve fertility outcomes and delays pregnancy.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
January 2025 in “Letters in Drug Design & Discovery” Ozonated olive oil may effectively treat fungal skin infections.
August 2013 in “Nature Reviews Drug Discovery” New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.
June 2003 in “Obstetrical & Gynecological Survey” After chemotherapy for a gestational trophoblastic tumor, normal pregnancy rates are possible, but there's a slightly higher risk of the tumor reoccurring in future pregnancies.
159 citations
,
July 2014 in “Molecular pharmaceutics” New micelle nanocarriers deliver Tacrolimus more effectively to skin layers for psoriasis treatment than the current Protopic ointment.
September 2009 in “European Urology Supplements” IGRT resulted in lower acute toxicity for stage III prostate cancer patients.
67 citations
,
September 2001 in “American Journal Of Pathology” Inhibiting ODC can prevent UV-induced skin cancer.
53 citations
,
August 2014 in “Cochrane library” Methotrexate is not proven effective for inducing remission in ulcerative colitis.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
21 citations
,
November 2021 in “Cells” Hedgehog pathway inhibitors can treat certain aggressive cancers but face limitations like resistance and side effects.
1 citations
,
September 2022 in “BioNanoScience” Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.
1 citations
,
September 2015 Gefitinib treatment led to unexpected hair growth in two lung cancer patients.
December 2025 in “Meditsinskiy sovet = Medical Council” Early diagnosis and multidisciplinary care are crucial for managing CNOT3 syndrome.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
1 citations
,
June 2025 in “Cell Biochemistry and Biophysics”